Home > News > Biophan Receives 'Buy' Rating
August 31st, 2005
Biophan Receives 'Buy' Rating
Abstract:
Biophan Technologies, Inc. (OTCBB: BIPH - News), a developer of next-generation biomedical technology, has received an unqualified "buy" rating in an independent, third-party research report written by a leading German analyst, MIDAS Research GmbH.
Source:
businesswire
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||